37 results about "BTLA" patented technology

The invention discloses an MUC1-CAR-T cell for co-expressing a BTLA / IL-18R chimeric receptor as well as a preparation method and application of the MUC1-CAR-T cell, and belongs to the technical field of biological medicines. The MUC1-CAR-T cell comprises a BTLA / IL-18R chimeric receptor and an MUC1-CAR structure, wherein the BTLA / IL-18R chimeric receptor is a BTLA MUC1 is used as a targeting molecule for CAR-T cell therapy, an extracellular domain of BTLA is connected with a transmembrane domain and an intracellular domain of an IL-18 receptor, and the co-expression BTLA / IL-18R chimeric receptor is designed. Experimental verification shows that the BTLA / IL-18R chimeric receptor can significantly improve the tumor killing ability of MUC1-CAR-T cells, can better inhibit the growth of tumors, and provides a novel immunotherapy strategy for the treatment of pancreatic cancer.

A BTLA-binding agent and immunoglobulin heavy chain and light chain polypeptides of the binding agent, as well as methods of using the BTLA-binding agent to treat a disorder or disease that is responsive to BTLA agonism, such as an autoimmune or inflammatory disease.

The application provides guidance and navigation control (GNC) proteins. In one embodiment, the GNC protein Comprises a T-cell binding moiety and a cancer-targeting moiety, wherein the T-cell binding moiety has a binding specificity to a T-cell receptor comprising CD3, CD28, PDL1, PD1, OX40, 4-1BB, GITR, TIGIT, TIM-3, LAG-3, CTLA4, CD40, VISTA, ICOS, BTLA, Light, NKp30, CD28H, CD27, CD226, CD96, CD112R, A2AR, CD160, CD244, CECAM1, CD200R, TNFRSF25 (DR3), or a combination thereof, and wherein the cancer targeting moiety has a binding specificity to a cancer cell receptor.

The invention discloses an amplification culture solution of TILs cells and a culture method thereof. The amplification culture solution comprises a complete culture medium, and an anti-BTLA antibody with the final concentration of 0.1-10 [mu] g / mL, penicillin with the final concentration of 50-500 [mu] g / mL, streptomycin with the final concentration of 50-500 [mu] g / mL, gentamicin with the final concentration of 10-100 [mu] g / mL and amphotericin with the final concentration of 1-50 [mu] g / mL are added into the complete culture medium. The anti-BTLA antibody component in the culture solution can relieve inhibition of BTLA on T cells by blocking combination of BTLA and a ligand HVEM of BTLA, so that the anti-tumor capability of TILs is enhanced; meanwhile, after the BTLA is combined with the ligand HVEM, T cell activation and proliferation can be inhibited, and rapid proliferation of TILs is promoted; the irradiation PBMC added in the TILs cell culture process can provide an activation signal for the TILs and drive rapid proliferation of the TILs cells.

The present invention provides isolated polypeptides capable of specifically binding to a protein target selected from LGALS9, CRP, BTLA, SAA, EGF, or FGA, or to a peptide thereof, especially under urinary conditions, which may be used for predicting in a urine sample of a subject suspected of having an infection whether the infection is a bacterial infection or a viral infection. The present invention further provides methods of diagnostics and treatment using the isolated polypeptides, and suitable diagnostic kits.

The present invention relates to anti-human BTLA agonist antibodies and their use for the prevention or treatment of inflammatory or autoimmune diseases or disorders such as systemic lupus erythematosus or graft versus host disease.

A method of treating a proliferative disease or condition in a subject comprising co-administering 5-(2-((5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)amino)-5-fluoropyrimidin-4-yl)-N,4-dimethylthiazol-2-amine (or a pharma- ceutically acceptable salt, solvate, or prodrug thereof) with an immunotherapeutic agent to the subject. The immunotherapeutic agent can be an immune checkpoint inhibitor, such as one capable of inhibiting PD-1, PD-L1 / 2, CTLA-4, BTLA, or Tim-3 and / or one or more of their ligands. Pharmaceutical compositions and kits are also disclosed.

The present invention provides novel anti-BTLA antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions in the treatment of diseases, such as cancer or autoimmune diseases.

The invention provides application of a BTLA inhibitor in preparation of a medicine for preventing and / or treating chronic hepatitis B, and belongs to the technical field of biological medicine. Research finds that antagonistic B and T lymphocyte attenuation factors (BTLA) can promote removal of hepatitis B surface antigen (HBsAg), reduce the expression level of HBeAg, promote activation and proliferation of T cells and enhance host immune response, so that the purpose of preventing and / or treating chronic hepatitis B is achieved, and functional cure of chronic hepatitis B (CHB) is achieved. The invention provides more choices for medicines for clinically preventing and / or treating chronic hepatitis B.

To provide novel anti-BTLA antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.SOLUTION: Provided are antibodies comprising a heavy chain variable region comprising a specific amino acid sequence and a light chain variable region comprising another specific amino acid sequence, pharmaceutical compositions comprising the antibodies, and therapeutic methods of using the antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.SELECTED DRAWING: Figure 1

The present invention provides a stable anti-BTLA (B and T lymphocyte attenuator) antibody pharmaceutical composition and its pharmaceutical use. The pharmaceutical composition comprises an anti-BTLA antibody, a buffer, and may further comprise at least one stabilizer and, optionally, a surfactant.

Provided are agents that bind to HVEM, inhibit HVEM-BTLA interactions, and activate downstream HVEM signaling. Also provided are methods of treating disease using those agents and kits containing those agents.

Provided are monoclonal antibodies and antigen-binding fragments thereof specific for BTLA, and methods of using same to treat autoimmune diseases, including combination therapies.

A method of treating a proliferative disease or condition in a subject, comprising co-administering to the subject a compound of formula I shown below (or a pharmaceutically acceptable salt, solvate or prodrug thereof): with an immunotherapeutic agent, for example an immune checkpoint inhibitor such as one capable of inhibiting PD-1, PD-L1 / 2, CTLA-4, BTLA or Tim-3 and / or one or more of the ligands thereof. Pharmaceutical compositions and kits are also disclosed.

The present invention generally relates to antibodies or antigen-binding fragments that bind to human B and T lymphocyte attenuator (BTLA) and their uses. More specifically, the present invention relates to agonistic antibodies that bind to human BTLA and modulate its activity, and their use in treating inflammatory, autoimmune and proliferative diseases and disorders.

The application discloses a kind of MUC1-CAR-T cells of co-expression BTLA / IL-18R chimeric receptor and preparation method and application thereof, belong to the field of biological medicine technology.The MUC1-CAR-T cell includes BTLA / IL-18R chimeric receptor and MUC1-CAR structure;The present application uses MUC1 as the targeting molecule of CAR-T cell treatment, the extracellular segment of BTLA is connected with the transmembrane region and intracellular section region of IL-18 receptor, and designs co-expression BTLA / IL-18R chimeric receptor.Experiment verifies and finds that BTLA / IL-18R chimeric receptor can significantly improve the tumor killing ability of MUC1-CAR-T cell, can better inhibit the growth of tumor, provides a new immunotherapy strategy for the treatment of pancreatic cancer.

This invention provides novel and useful agents capable of modulating human B and T lymphocyte attenuation factors (BTLA). [Solution] The present invention generally relates to antibodies or antigen-binding fragments that bind to BTLA, and to the use thereof. More specifically, the present invention relates to agonist antibodies that bind to human BTLA and modulate its activity, and to the use thereof in treating inflammatory, autoimmune, and proliferative diseases and disorders.

The present invention provides novel anti-BTLA antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods for treating diseases (eg, cancer or autoimmune diseases) using such antibodies and pharmaceutical compositions.

The present invention relates to anti-BTLA antibodies. The present invention relates generally to antibodies or antigen-binding fragments that bind to human B and T lymphocyte attenuators (BTLAs) and uses thereof. More specifically, the present invention relates to agonistic antibodies that bind to and modulate the activity of human BTLA, and their use in the treatment of inflammatory, autoimmune and proliferative diseases and disorders.

The invention provides monoclonal antibodies and antigen-binding fragments thereof specific for BTLA, and methods of using the same to treat autoimmune disorder, including combination therapy.

Administering to a subject a compound of Formula I (or a pharma- ceutically acceptable salt, solvate, or prodrug thereof), as shown below: [Formula 1] and a method of treating a proliferative disease or condition in said subject, comprising co-administering TIFF2025509577000012.tif37165 with an immunotherapeutic agent, e.g., an immune checkpoint inhibitor, e.g., capable of inhibiting PD-1, PD-L1 / 2, CTLA-4, BTLA, or Tim-3 and / or one or more of their ligands. Pharmaceutical compositions and kits are also disclosed.

To provide new and useful agents, such as antibodies or antigen-binding antibody fragments, capable of modulating the BTLA.SOLUTION: The invention provides: agonistic antibodies that bind the human B and T lymphocyte attenuator (BTLA)and modulate its activity; and their use in treating inflammatory, autoimmune and proliferative diseases and disorders.SELECTED DRAWING: None

Described herein are treatments and preventions for autoimmune disease or inflammatory disease using agonistic antibodies that bind to BTLA, and uses of an anti-BTLA antibody in the manufacture of a medicament for the treatment or prevention of an autoimmune disease or inflammatory disease. Also described herein are methods of agonizing BTLA activity without blocking or preventing the binding of HVEM to BTLA by administering an agonistic antibody that binds to BTLA.

The present application provides antibodies including antigen binding fragments thereof that specifically recognize B- and T-lymphocyte attenuator (BTLA). Also provided are methods of making and using these antibodies

A method of treating a proliferative disease or condition in a subject, comprising co-administering 5−(2-((5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)amino)-5-fluoropyrimidin-4-yl)-N,4-dimethylthiazol-2-amine (or a pharmaceutically acceptable salt, solvate or prodrug thereof) with an immunotherapeutic agent to the subject. The immunotherapeutic agent may be an immune checkpoint inhibitor such as one capable of inhibiting PD-1, PD-L1 / 2, CTLA-4, BTLA or Tim-3 and / or one or more of the ligands thereof. Pharmaceutical compositions and kits are also disclosed.

The present invention relates to anti-human BTLA agonist antibodies and their use to prevent or treat inflammatory or autoimmune diseases or disorders, such as systemic lupus erythematosus or graft-versus-host disease.

The present invention relates to antisense oligonucleotides for modulating the function of a T cell, including antisense oligonucleotides that hybridise to IFN-γ, granzyme, perforin 1, PD-1, PRDM1, PD-L1, CD40LG, NDFIP1, PDCD1 LG2, REL, BTLA, CD80, CD160, CD244, LAG3, TIGIT, ADORA2A & TIM-3 RNAs. In particular, the present invention relates to antisense oligonucleotides capable of inducing exon skipping of RNA. Also claimed is a method for further modifying the specificity of said T-cell by providing for a T cell receptor gene.

The invention belongs to the technical field of biological medicines, and particularly relates to engineered platelets, a preparation method thereof and application of the engineered platelets in type 1 diabetes mellitus. According to the engineering blood platelet, PD-L1 protein, PD-L2 protein, BTLA protein and Galectin-9 protein are overexpressed, and the engineering blood platelet is prepared by adopting a cell factor IFN-gamma to stimulate megakaryocyte. Experiments find that engineered platelets over-expressing PD-L1, PD-L2, BTLA and Galectin-9 molecules can accumulate in inflamed pancreatic tissues and inhibit the activity of pancreatic autoreactive T cells, so that beta-cells producing insulin are protected from being attacked, the beta-cells can be rescued by intervening an immune system, insulin secretion is recovered, and the effect of preventing and treating insulin is achieved. Therefore, the blood sugar of the NOD mouse is kept at a normal level, the treatment of newborn type 1 diabetes is realized, and the medicine has a very good treatment effect when being applied to the treatment of diabetes.

The present application relates to the technical field of antibodies, in particular to anti-HVEM antibodies or fragments thereof and their uses. The technical problem solved by the present application is to provide a series of BTLA blocking anti-HVEM antibodies or fragments thereof. The anti-HVEM antibodies of the present application have good affinity, specificity and functional activity, can block the binding of BTLA to HVEM, promote the activation of T cells, and have application potential in cancer treatment.

The invention relates to an anti-BTLA nano antibody in the technical field of biological medicines. The amino acid sequence of the nano antibody is selected from one of SEQ ID No: 1, SEQ ID No: 2 or SEQ ID No: 3. The preparation method comprises three steps of BTLA antigen purification, phage display library panning and nano antibody expression purification, a high-purity antigen is obtained through secondary purification of Ni resin and an anion column, high-affinity clone is screened through four rounds of panning and ELISA verification, and a final product is high in purity and stable in yield. The nano antibody has the advantages of high specificity, high stability, excellent tissue penetrability and low-cost production, can efficiently block a BTLA-HVEM channel and activate T cell immune response, has a remarkable effect in treatment of tumors such as melanoma and lymphoma and rheumatoid arthritis, can be used as an ELISA or immunohistochemical reagent to detect the BTLA expression level, and has a wide application prospect. Important clinical application values and commercial prospects are realized.